Anthony Molloy - Apr 6, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Lgl & Compliance Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Apr 6, 2022
Transactions value $
-$801,985
Form type
4
Date filed
4/8/2022, 04:16 PM
Previous filing
Jan 20, 2022
Next filing
Jun 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $121K +3K +17.09% $40.34 20.6K Apr 6, 2022 Direct F1
transaction PCRX Common Stock Options Exercise $442K +10K +48.66% $44.20 30.6K Apr 6, 2022 Direct F1
transaction PCRX Common Stock Options Exercise $85.9K +2.5K +8.18% $34.38 33.1K Apr 6, 2022 Direct F1
transaction PCRX Common Stock Options Exercise $268K +7K +21.18% $38.35 40.1K Apr 6, 2022 Direct F1
transaction PCRX Common Stock Sale -$1.22M -16.1K -40.1% $76.03 24K Apr 6, 2022 Direct F1, F2
transaction PCRX Common Stock Sale -$303K -3.94K -16.41% $77.03 20.1K Apr 6, 2022 Direct F1, F3
transaction PCRX Common Stock Sale -$195K -2.5K -12.48% $77.94 17.6K Apr 6, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -3K -100% $0.00* 0 Apr 6, 2022 Common Stock 3K $40.34 Direct F5
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -10K -100% $0.00* 0 Apr 6, 2022 Common Stock 10K $44.20 Direct F5
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2.5K -80% $0.00 625 Apr 6, 2022 Common Stock 2.5K $34.38 Direct F6
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -7K -80% $0.00 1.75K Apr 6, 2022 Common Stock 7K $38.35 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.55 to $76.53, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.58 to $77.57, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.585 to $78.490, inclusive.
F5 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.
F6 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.